Trial Profile
A phase II, single arm, multicenter study of nilotinib in combination with pegylated interferon alpha2b in patients with suboptimal molecular response or stable detectable molecular residual disease after at least two years of imatinib treatment (NordDutchCML009)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 13 May 2022
Price :
$35
*
At a glance
- Drugs Nilotinib (Primary) ; Peginterferon alfa-2b (Primary)
- Indications Chronic myeloid leukaemia
- Focus Biomarker; Pharmacodynamics; Pharmacogenomic; Therapeutic Use
- Acronyms NordDutchCML009
- 25 Jun 2017 Results presented at the 22nd Congress of the European Haematology Association
- 25 Jun 2017 Status changed from recruiting to discontinued as the recruitment of patients was difficult, according the results presented at the 22nd Congress of the European Haematology Association
- 02 Feb 2017 This trial was discontinued in Netherlands, according to European Clinical Trials Database.